In a nutshell This phase 2 trial will evaluate the safety and effectiveness of pirfenidone (Esbriet) for the treatment of interstitial lung disease in patients with rheumatoid arthritis. The main outcome to be investigated is the level of lung disease progression. The details Although rheumatoid arthritis (RA) primarily affects the joints,...
Read MoreSymptom(s) not related to joints-Symptomatic inflammatory conditions-Shortness of breath and a dry cough Posts on Medivizor
